Aurinia Pharmaceuticals announced a board restructuring to align with shareholder interests, appointing Kevin Tang of Tang Capital Management as a new director.1
Peter Greenleaf, President and CEO, remains a director despite conditional resignation after receiving less than majority support at the 2024 AGM; the board rejected it in the company's best interests.1
The board accepted resignations of directors Daniel G. Billen, R. Hector MacKay-Dunn, and Brinda Balakrishnan, resulting in a seven-member board including Tang and Greenleaf.1
No evidence in recent reports confirms the CEO or C-suite departing; Greenleaf explicitly retains his CEO role and directorship.1
Separately, Aurinia sued former FDA CDER director George Tidmarsh for defamation over a LinkedIn post criticizing their drug Lupkynis, linked to a past vendetta against chairman Kevin Tang from prior companies.23
Sources:
1. https://www.auriniapharma.com/press-releases/aurinia-announces-board-restructuring
2. https://themedicinemaker.com/issues/2025/articles/november/george-tidmarsh-fda-resignation-and-lawsuit
3. https://www.insurancejournal.com/news/national/2025/11/05/846442.htm